The adoptive immune response and protumorigenic inflammation gene signatures are associated with spatial organization of immune cells in the tumor microenvironment.
Dr. Matthew Galsky and colleagues uncovered gene signatures representing adaptive immunity and pro-tumorigenic inflammation that were responsible for sensitivity or resistance to immune checkpoint inhibitors. The findings enabled identification of biomarkers in patients who are less likely to respond favorably to immune checkpoint inhibitors, as well as new combination therapeutic approaches that might overcome such resistance in those patients.
